AANEM News Express

AANEM News Express

Science News: Rise of Biomarkers – Part 3

11/21/2017
 
Submitted and edited by Francisco Gomez, MD, News Science Editorial Board

Over the past several months, an ever increasing number of articles on biomarkers have been published. The AANEM News Science Editorial Board is striving to keep our readers abreast of these recent discoveries.
 
In “Rise of the Biomarkers – Part 3” (of a four-part series), biomarkers for Charcot-Marie-Tooth disease 1A are discussed.
___
 
Fledrich R, Mannil M, Leha A, et al. Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A.
J Neurol Neurosurg Psychiatry 2017;88:941-952.
 
CMT is the most common inheritable neuropathy following a slowly demyelinating course, which has variable progression and severity, even among dizygotic twins.
 
This paper sought to evaluate biomarkers for the evaluation of CMT1A severity and prognosis. Investigators conducted a multi-center trial, collecting 311 CMT patients from 9 centers in total, 58% female with a median age of 43 years. They conducted CMT neuropathy scores and neuropathology studies via skin biopsies. A distinct cutaneous gene expression profile emerged with mRNA clusters correlating both with each other and with disease severity CDA, CTSA, GRIA1, ENPP1, ANPEP, FN3KRP, GSTT2, PPAR6. In addition, they found a gene expression cluster correlating with disease progression after 2-3 years in a 45 patient follow-up cohort (GSTT2, CTSA, PPAR6, CDA, ENPP1, NRG1). Investigators concluded that not only are skin biopsy derived biomarkers viable for prognostication and severity determination in CMT1A, but that said markers may be of use in future assays as objective measures.
 
Comment: This study not only opens a new door for CMT1A biomarkers as a step forward in prognostication of the disease, but, as the authors sagely note, may increase the sensitivity of future studies via an objective measurement of progression. 


View Related News Stories:

  EducationScience News


Recent AANEM News

Recap: 2019 AMA House of Delegates Annual Meeting

Science News: Efficacy of Botulinum Toxin A for Treating Cramps in Diabetic Neuropathy

Science News: Diagnostic Sensitivity of Electrophysiology and Ultrasonography in Ulnar Neuropathies of Different Severity

Science News: Long-term Effect of Thymectomy Plus Prednisone Versus Prednisone Alone in Patients with Non-thymomatous Myasthenia Gravis: 2-year Extension of the MGTX Randomised Trial

AANEM Returns to Capitol for 6th Annual Hill Day





Advertisement

TPP

Advertisement

ABEM

Advertisement

Find Your Dream Job